S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
Biden signs bill extending a key US surveillance program after divisions nearly forced it to lapse
MarketBeat Week in Review – 4/15 - 4/19
The drug war devastated Black and other minority communities. Is marijuana legalization helping?
Morning sickness? Prenatal check-ups? What to know about new rights for pregnant workers
A man escaped Sudan's bloody civil war. His mysterious death in Missisippi has sparked suspicion
Record Store Day celebrates indie retail music sellers as they ride vinyl's popularity wave
Panama Papers trial's public portion comes to an unexpectedly speedy end
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
Biden signs bill extending a key US surveillance program after divisions nearly forced it to lapse
MarketBeat Week in Review – 4/15 - 4/19
The drug war devastated Black and other minority communities. Is marijuana legalization helping?
Morning sickness? Prenatal check-ups? What to know about new rights for pregnant workers
A man escaped Sudan's bloody civil war. His mysterious death in Missisippi has sparked suspicion
Record Store Day celebrates indie retail music sellers as they ride vinyl's popularity wave
Panama Papers trial's public portion comes to an unexpectedly speedy end
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
Biden signs bill extending a key US surveillance program after divisions nearly forced it to lapse
MarketBeat Week in Review – 4/15 - 4/19
The drug war devastated Black and other minority communities. Is marijuana legalization helping?
Morning sickness? Prenatal check-ups? What to know about new rights for pregnant workers
A man escaped Sudan's bloody civil war. His mysterious death in Missisippi has sparked suspicion
Record Store Day celebrates indie retail music sellers as they ride vinyl's popularity wave
Panama Papers trial's public portion comes to an unexpectedly speedy end
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
Biden signs bill extending a key US surveillance program after divisions nearly forced it to lapse
MarketBeat Week in Review – 4/15 - 4/19
The drug war devastated Black and other minority communities. Is marijuana legalization helping?
Morning sickness? Prenatal check-ups? What to know about new rights for pregnant workers
A man escaped Sudan's bloody civil war. His mysterious death in Missisippi has sparked suspicion
Record Store Day celebrates indie retail music sellers as they ride vinyl's popularity wave
Panama Papers trial's public portion comes to an unexpectedly speedy end
NASDAQ:GEHC

GE HealthCare Technologies (GEHC) Stock Price, News & Analysis

$84.49
-0.48 (-0.56%)
(As of 04/19/2024 ET)
Today's Range
$84.10
$85.61
50-Day Range
$82.31
$93.87
52-Week Range
$62.35
$94.50
Volume
2.02 million shs
Average Volume
2.57 million shs
Market Capitalization
$38.56 billion
P/E Ratio
27.98
Dividend Yield
0.14%
Price Target
$95.09

GE HealthCare Technologies MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.64 Rating Score
Upside/​Downside
12.5% Upside
$95.09 Price Target
Short Interest
Healthy
2.87% of Float Sold Short
Dividend Strength
Weak
Based on Four Factors
Sustainability
N/A
News Sentiment
1.11mentions of GE HealthCare Technologies in the last 14 days
Based on 9 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
12.56%
From $4.30 to $4.84 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.09 out of 5 stars

Medical Sector

160th out of 911 stocks

X-Ray Apparatus & Tubes Industry

2nd out of 4 stocks

GEHC stock logo

About GE HealthCare Technologies Stock (NASDAQ:GEHC)

GE HealthCare Technologies Inc. is a leading player in the medical industry, specializing in developing and manufacturing advanced healthcare technologies. With a strong commitment to improving patient outcomes and advancing medical science, the company has established itself as a trusted provider of innovative solutions for healthcare professionals worldwide.

The mission of GE HealthCare Technologies Inc. is to revolutionize healthcare through cutting-edge technology and collaboration. By leveraging its expertise in medical imaging, diagnostics, and biopharmaceutical manufacturing, the company aims to enable healthcare providers to deliver more precise diagnoses, personalized treatment options, and better patient care.

Headquartered in Chicago, Illinois, GE HealthCare Technologies Inc. has a global presence, with operations spanning multiple countries. Its products and services cater to various medical specialties, including radiology, cardiology, oncology, neurology, and more. The company's comprehensive portfolio encompasses medical imaging systems, diagnostic tools, pharmaceutical manufacturing equipment, and digital health solutions.

GE HealthCare Technologies Inc. serves a diverse customer base, including hospitals, clinics, research institutions, and pharmaceutical companies. The company has established strategic partnerships with leading healthcare providers and organizations to drive collaborative innovation and address pressing healthcare challenges.

GE HealthCare Technologies Inc. is led by a dynamic management team with extensive experience in the healthcare industry. The company's Chief Executive Officer (CEO) is Peter Arduini, a seasoned executive known for his strategic vision and operational expertise. Under his leadership, GE HealthCare Technologies Inc. has consistently pursued innovation and growth opportunities.

Jan Makela serves as the CEO of Imaging, overseeing the company's imaging solutions portfolio. With a strong background in medical technology and a focus on customer-centric innovation, Makela has played a crucial role in developing cutting-edge imaging technologies.

GE HealthCare Technologies Inc. has demonstrated strong financial performance in recent years, with consistent revenue growth and solid profit margins. The company's annual sales reached an impressive $18.34 billion in 2022, reflecting its position as a key player in the medical technology industry.

GE HealthCare Technologies Inc. has maintained a healthy financial position, with a favorable price-to-earnings ratio, indicating investor confidence in the company's future earnings potential. The forward-looking price-to-earnings-growth ratio of 3 suggests that the company is well-positioned for sustainable long-term growth.

The company's profitability is further highlighted by its impressive price-to-sales ratio, which indicates that investors are willing to pay a premium for GE HealthCare Technologies Inc.'s products and services. The company's strong cash flow position demonstrates the company's ability to generate substantial cash and reinvest in research and development initiatives.

GE HealthCare Technologies Inc. operates within the broader medical technology industry, encompassing various sub-sectors such as medical imaging, diagnostics, and biopharmaceutical manufacturing. This industry is characterized by rapid technological advancements, increasing demand for innovative solutions, and a growing emphasis on personalized patient care.

Competitors in the medical technology sector include established companies such as Siemens Healthineers, Philips Healthcare, Medtronic, and smaller niche players. GE Healthcare Technologies Inc. distinguishes itself through its diverse product portfolio, global presence, and commitment to continuous innovation.

The company's competitive advantage lies in its strong research and development capabilities, technological expertise, and strategic partnerships. These factors enable GE HealthCare Technologies Inc. to introduce cutting-edge solutions, improve patient outcomes and maintain a strong market position.

GE HealthCare Technologies Inc. is well-positioned to seize growth opportunities in the medical technology industry. The company can capitalize on several factors, including advancements in artificial intelligence and machine learning, increased demand for digital health solutions, and the rising prevalence of chronic diseases.

By leveraging its technological expertise, GE HealthCare can continue to develop innovative products and services that address these industry trends. Additionally, expanding into emerging markets, forging strategic partnerships, and pursuing acquisitions can provide avenues for further growth and market expansion.

While GE HealthCare Technologies Inc. has demonstrated resilience and growth potential, it faces risks and challenges inherent to the medical technology industry. Regulatory changes, evolving reimbursement models, and intense competition can impact the company's operations and profitability.

To mitigate these risks, GE HealthCare Technologies Inc. employs robust risk management strategies, including continuous monitoring of regulatory developments, diversification of product offerings, and proactive engagement with healthcare stakeholders. The company's strong research and development capabilities and focus on innovation allow it to adapt to evolving market dynamics and stay ahead of the competition.

GEHC Stock Price History

GEHC Stock News Headlines

Nvidia's AI Tech Part of Novo Nordisk's New Supercomputer (GEHC)
Novo Nordisk and Nvidia have teamed up to develop supercomputers, aiming to accelerate drug discovery development using advanced AI technologies.
Tiny Biotech Stock Wins $75 Billion Patent
A little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda.
GE HealthCare Technologies (NASDAQ:GEHC) PT Raised to $110.00
Tiny Biotech Stock Wins $75 Billion Patent
A little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda.
GEHC Mar 2024 81.000 call
GEHC Mar 2024 85.000 put
See More Headlines
Receive GEHC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for GE HealthCare Technologies and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Ex-Dividend for 2/15 Dividend
1/12/2024
Last Earnings
2/06/2024
Dividend Payable
2/15/2024
Ex-Dividend for 5/15 Dividend
4/18/2024
Today
4/20/2024
Next Earnings (Confirmed)
4/30/2024
Dividend Payable
5/15/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
X-ray apparatus & tubes
Sub-Industry
N/A
Current Symbol
NASDAQ:GEHC
Fax
N/A
Employees
51,000
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$95.09
High Stock Price Target
$110.00
Low Stock Price Target
$80.00
Potential Upside/Downside
+12.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.64
Research Coverage
11 Analysts

Profitability

Net Income
$1.57 billion
Pretax Margin
12.07%

Debt

Sales & Book Value

Annual Sales
$19.55 billion
Cash Flow
$5.25 per share
Book Value
$15.69 per share

Miscellaneous

Free Float
455,096,000
Market Cap
$38.56 billion
Optionable
Optionable
Beta
0.94
(Almost) Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

  • Mr. Peter J. Arduini (Age 59)
    President, CEO & Director
    Comp: $2.26M
  • Mr. Frank R. Jimenez Esq. (Age 59)
    General Counsel & Corporate Secretary
    Comp: $1.85M
  • Mr. Jan Makela (Age 55)
    Chief Executive Officer of Imaging
    Comp: $955.06k
  • Mr. James K. Saccaro (Age 51)
    VP & CFO
  • Mr. George Andrew Newcomb (Age 57)
    Controller & Chief Accounting Officer
  • Dr. Taha Kass-Hout M.D. (Age 51)
    M.S., Chief Science & Technology Officer
  • Mr. Thomas J. Westrick (Age 55)
    Chief Executive Officer of Patient Care Solutions
  • Mr. Kevin M. O'Neill (Age 55)
    Chief Executive Officer of Pharmaceutical Diagnostics
  • Mr. Roland Rott (Age 52)
    CEO of Ultrasound
  • Mr. Kenneth R. Stacherski (Age 52)
    Chief Global Supply Chain & Service Officer

Should I Buy GE HealthCare Technologies Stock? GEHC Pros and Cons Explained

Pros

Here are some ways that investors could benefit from investing in GE HealthCare Technologies Inc.:

  • GE HealthCare Technologies Inc. reported strong quarterly earnings, beating analysts' estimates, indicating financial stability and growth potential.
  • The company operates in multiple segments such as Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics, diversifying its revenue streams and reducing risk.
  • GE HealthCare Technologies Inc. has a solid return on equity of 25.58%, showcasing efficient use of shareholder funds to generate profits.
  • The stock has shown a consistent upward trend with a 52-week high of $94.50, indicating positive investor sentiment and potential for capital appreciation.
  • GE HealthCare Technologies Inc. offers a wide range of products and services in the healthcare industry, catering to various medical needs and potentially capturing a larger market share.

Cons

Investors should be bearish about investing in GE HealthCare Technologies Inc. for these reasons:

  • The company's stock price has experienced fluctuations, with a 52-week low of $62.35, indicating volatility and potential risks associated with investing in the company.
  • GE HealthCare Technologies Inc. operates in a highly competitive industry with rapid technological advancements, which may pose challenges in maintaining market share and profitability.
  • There is a debt-to-equity ratio of 1.18, suggesting that the company relies on debt financing, which can increase financial risk and interest expenses.
  • Market conditions and regulatory changes in the healthcare sector can impact the company's operations and financial performance, leading to uncertainties for investors.
  • Investors should consider the company's price-to-earnings-growth ratio of 3.26, which indicates the stock may be overvalued relative to its growth prospects, potentially limiting future returns.
These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Saturday, April 13, 2024. Please send any questions or comments about these GE HealthCare Technologies pros and cons to contact@marketbeat.com.

GEHC Stock Analysis - Frequently Asked Questions

Should I buy or sell GE HealthCare Technologies stock right now?

11 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for GE HealthCare Technologies in the last year. There are currently 4 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" GEHC shares.
View GEHC analyst ratings
or view top-rated stocks.

What is GE HealthCare Technologies' stock price target for 2024?

11 Wall Street analysts have issued 12 month price objectives for GE HealthCare Technologies' shares. Their GEHC share price targets range from $80.00 to $110.00. On average, they predict the company's stock price to reach $95.09 in the next year. This suggests a possible upside of 12.5% from the stock's current price.
View analysts price targets for GEHC
or view top-rated stocks among Wall Street analysts.

How have GEHC shares performed in 2024?

GE HealthCare Technologies' stock was trading at $77.32 at the beginning of 2024. Since then, GEHC stock has increased by 9.3% and is now trading at $84.49.
View the best growth stocks for 2024 here
.

When is GE HealthCare Technologies' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, April 30th 2024.
View our GEHC earnings forecast
.

How can I listen to GE HealthCare Technologies' earnings call?

GE HealthCare Technologies will be holding an earnings conference call on Tuesday, April 30th at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link.

How were GE HealthCare Technologies' earnings last quarter?

GE HealthCare Technologies Inc. (NASDAQ:GEHC) posted its earnings results on Tuesday, February, 6th. The company reported $1.18 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.07 by $0.11. The company earned $5.20 billion during the quarter, compared to the consensus estimate of $5.09 billion. GE HealthCare Technologies had a trailing twelve-month return on equity of 25.58% and a net margin of 8.02%. The business's quarterly revenue was up 5.3% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.31 EPS.

How often does GE HealthCare Technologies pay dividends? What is the dividend yield for GE HealthCare Technologies?

GE HealthCare Technologies declared a quarterly dividend on Friday, March 22nd. Stockholders of record on Friday, April 19th will be given a dividend of $0.03 per share on Wednesday, May 15th. This represents a $0.12 dividend on an annualized basis and a dividend yield of 0.14%. The ex-dividend date of this dividend is Thursday, April 18th.
Read our dividend analysis for GEHC
.

Is GE HealthCare Technologies a good dividend stock?

GE HealthCare Technologies (NASDAQ:GEHC) pays an annual dividend of $0.12 per share and currently has a dividend yield of 0.14%. The dividend payout ratio is 3.97%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, GEHC will have a dividend payout ratio of 2.48% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for GEHC.

What guidance has GE HealthCare Technologies issued on next quarter's earnings?

GE HealthCare Technologies updated its FY24 earnings guidance on Tuesday, February, 6th. The company provided earnings per share (EPS) guidance of $4.20-$4.35 for the period, compared to the consensus estimate of $4.24.

Who are GE HealthCare Technologies' major shareholders?

GE HealthCare Technologies' stock is owned by many different retail and institutional investors. Top institutional shareholders include Perpetual Ltd (0.23%), Sumitomo Mitsui Trust Holdings Inc. (0.22%), GuoLine Advisory Pte Ltd (0.10%), Douglas Lane & Associates LLC (0.10%), AMF Tjanstepension AB (0.09%) and Wealth Enhancement Advisory Services LLC (0.04%). Insiders that own company stock include H Lawrence Culp Jr, Jan Makela, Kevin Michael O'neill and Roland Rott.
View institutional ownership trends
.

How do I buy shares of GE HealthCare Technologies?

Shares of GEHC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:GEHC) was last updated on 4/20/2024 by MarketBeat.com Staff

From Our Partners